Neurvati Neurosciences

Meet the Neurvati and GRIN Therapeutics, Inc. team at the International League Against Epilepsy’s 15th European Epilepsy Congress as we present new data from our Phase 1b Honeycomb clinical trial evaluating our investigational drug as a potential treatment for children with GRIN-related disorder. #EEC2024

#Neurotechnology, the fusion of #neuroscience and technology, is revolutionizing the way we understand and interact with the human brain. Looking ahead, several neurotechnological advancements are poised to penetrate the market and transform #healthcare. In this Forbes article, discover five pivotal trends in neurotechnology: neurofeedback, functional magnetic resonance imaging (fMRI), brain-computer interfaces (BCIs), transcranial magnetic stimulation (TMS) and neuroprosthetics. As we optimize the development of neuroscience therapies, it is exciting to see the progress in neurotechnology. https://lnkd.in/gpnP4b_W

In this episode of the Biotech2050 podcast, our CEO Bruce Leuchter, M.D., spoke with co-host Alok Tayi, PhD, explore the convergence of #neurology and #psychiatry, advancements in drug development technologies, and how our innovative business model is structured to meet and overcome the unique challenges associated with neuroscience drug development. Tune in for insights on the future of #biotech and developments in #neuroscience: https://lnkd.in/e5ZH-V5H

In the past decade, many pharmaceutical companies halted #neuroscience drug development programs due to clinical failures, scientific barriers and decreased difficulty in attracting investor attention. However, in recent years, there has been a notable resurgence of interest in addressing #CNS disorders. Gene Kinney provides insights in this PharmaVoice article, exploring advancements in science and innovative approaches that are revitalizing the CNS therapeutic area. He also discusses the increasing momentum of partnerships and collaborations driving progress in this critical field. Read here: https://lnkd.in/gUpTtiC7

In this STAT article, our CEO Bruce Leuchter, M.D., outlines our innovative business model, which offers a distinct approach to advancing promising therapies in #neuroscience. This private equity model is based on a four-step process – search, evaluate, invest, develop – providing a high degree of flexibility that can position assets for a broad range of development opportunities.   Learn how our business model enhances efficiency and mitigates risks, accelerating the advancement of promising programs: https://lnkd.in/erMQz5fP

Recently, OneNeuro Initiative partnered with The Johns Hopkins University to announce the 2024 #OneNeuro Discovery Awardees.   As champions of #neuroscience innovation and collaboration, we are excited to see the OneNeuro Initiative foster a university-wide #neuroscience community at Johns Hopkins. This initiative leverages diverse minds and resources to deepen our knowledge of the brain and accelerate research for neurological and psychiatric disorders. Congratulations to the awardees! Lena Smirnova Seth Blackshaw Erin Jimenez

Today we join the World Federation Of Neurology in recognizing #WorldBrainDay. According to The Lancet Neurology, approximately 3.4 billion people worldwide are affected by neurological disorders, ranging from #dementia and #Alzheimers to #epilepsy and #stroke. This underscores the critical need for continued investment in R&D to advance more effective therapies for neurological diseases. This year’s theme is #BrainHealthandPrevention, and we are dedicated to optimizing the development of neuroscience therapies to improve patients' lives. During #WBD2024, join us as we advocate for increased education and treatment options for neurological disorders to pave the way for a brighter, healthier future.

Recently, Fierce Biotech released their 2024 Fundraising Tracker, capturing a significant surge in venture capital investments within the #biotech industry. With a focus on clinical trial results, special reports, and enterprise stories, there is a notable increase in fundraising rounds exceeding $50 million. The report highlights numerous milestones for companies focused on developing therapies for neurological diseases, Seeing the uptick in investor interest in #neuroscience research is promising and brings us closer to expanding treatment options for neurological diseases. Read the full report: https://lnkd.in/emutbyHy

We are embracing an innovative business model that has the potential to position a multitude of neurological therapies for clinical development based on promising research that has been deprioritized or abandoned for different reasons. #ICYMI, in The Pharma Letter's Expert View column, our CEO Bruce Leuchter, M.D., shares his insights on the importance of increased investment in research and highlights how we are leveraging an “identify-evaluate-invest-develop” approach to bring patients more therapies for neurological disorders. Read here: https://lnkd.in/eRrMs84G

Neurological diseases have become a leading cause of poor health and disability worldwide, underscoring the urgent need for enhanced research and innovative approaches in #neuroscience. Despite efforts focused on advancing treatment, progress has been disappointingly slow in part due to high risk of failure and often lengthy development timelines. When neuroscience drug developers are able to demonstrate confidence with solid early-to mid-stage data, investors are more inclined to engage, recognizing substantial market potential. Learn more in this STAT article as our Chief Executive Officer Bruce Leuchter, M.D., describes a private equity model, like the one we embrace, to support the advancement of promising neurotherapeutics:  https://lnkd.in/erMQz5fP